Gema López-Gallardo, Ana Piñar-Gutiérrez, Celia Hernández-Reina, Sandra Amuedo, Noelia Gros-Herguido, Pablo J. Remón-Ruiz, Virginia Bellido, Pilar Santa Cruz-Álvarez, Lucas Cerrillo, Alfonso Soto-Moreno
{"title":"1型糖尿病妇女的母体和胎儿结局与瞬时血糖监测指标相关:一项队列研究","authors":"Gema López-Gallardo, Ana Piñar-Gutiérrez, Celia Hernández-Reina, Sandra Amuedo, Noelia Gros-Herguido, Pablo J. Remón-Ruiz, Virginia Bellido, Pilar Santa Cruz-Álvarez, Lucas Cerrillo, Alfonso Soto-Moreno","doi":"10.1016/j.endien.2026.501804","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate the association between flash glucose monitoring (FGM) metrics and perinatal outcomes in pregnant women with type 1 diabetes (T1DM).</div></div><div><h3>Research design and methods</h3><div>This retrospective cohort study included pregnant women with T1DM who used FGM. The primary outcome was a composite endpoint including fetal or neonatal mortality, large-for-gestational-age (LGA) birth weight, neonatal intensive care unit (NICU) admission, or neonatal hypoglycemia. Glycated hemoglobin (HbA1c) levels were assessed together with time in range (TIR), time below range (TBR), and time above range (TAR) within pregnancy-specific glucose targets, as well as glucose variability.</div></div><div><h3>Results</h3><div>A total of 70 women were included, with a median age of 36 years (IQR, 31–38), body mass index (BMI) 27<!--> <!-->±<!--> <!-->5<!--> <!-->kg/m<sup>2</sup>, diabetes duration 20<!--> <!-->±<!--> <!-->8 years, and pregestational HbA1c 7.3<!--> <!-->±<!--> <!-->1.4%. Among them, 21.7% were smokers, 4.5% had hypertension, 10.1% had dyslipidemia, and 41.2% had diabetic retinopathy. Women who experienced the composite endpoint exhibited significantly lower TIR and higher TAR across all trimesters, greater glycemic variability (CV) during the first (1T) and third trimesters (3T), and a higher glucose management indicator (GMI) in the third trimester. Logistic regression analysis showed that a TIR<!--> <!--><<!--> <!-->69.5% during the second trimester (2T) increased the risk of the composite endpoint by 10.56-fold (<em>P</em> <!-->=<!--> <!-->.015). Similarly, CV<!--> <!-->≥<!--> <!-->31.85% during the first trimester was associated with a 6.42-fold increased risk (<em>P</em> <!-->=<!--> <!-->.039). A model combining these 2 variables achieved a sensitivity of 94.3% and a specificity of 50%.</div></div><div><h3>Conclusions</h3><div>Glycemic control assessed through FGM metrics, particularly TIR during the second trimester and CV during the first trimester, is associated with adverse maternal–fetal outcomes in pregnant women with T1DM.</div></div>","PeriodicalId":48650,"journal":{"name":"Endocrinologia Diabetes Y Nutricion","volume":"73 7","pages":"Article 501804"},"PeriodicalIF":1.9000,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Maternal and fetal outcomes associated with flash glucose monitoring metrics in women with type 1 diabetes: A cohort study\",\"authors\":\"Gema López-Gallardo, Ana Piñar-Gutiérrez, Celia Hernández-Reina, Sandra Amuedo, Noelia Gros-Herguido, Pablo J. Remón-Ruiz, Virginia Bellido, Pilar Santa Cruz-Álvarez, Lucas Cerrillo, Alfonso Soto-Moreno\",\"doi\":\"10.1016/j.endien.2026.501804\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><div>To evaluate the association between flash glucose monitoring (FGM) metrics and perinatal outcomes in pregnant women with type 1 diabetes (T1DM).</div></div><div><h3>Research design and methods</h3><div>This retrospective cohort study included pregnant women with T1DM who used FGM. The primary outcome was a composite endpoint including fetal or neonatal mortality, large-for-gestational-age (LGA) birth weight, neonatal intensive care unit (NICU) admission, or neonatal hypoglycemia. Glycated hemoglobin (HbA1c) levels were assessed together with time in range (TIR), time below range (TBR), and time above range (TAR) within pregnancy-specific glucose targets, as well as glucose variability.</div></div><div><h3>Results</h3><div>A total of 70 women were included, with a median age of 36 years (IQR, 31–38), body mass index (BMI) 27<!--> <!-->±<!--> <!-->5<!--> <!-->kg/m<sup>2</sup>, diabetes duration 20<!--> <!-->±<!--> <!-->8 years, and pregestational HbA1c 7.3<!--> <!-->±<!--> <!-->1.4%. Among them, 21.7% were smokers, 4.5% had hypertension, 10.1% had dyslipidemia, and 41.2% had diabetic retinopathy. Women who experienced the composite endpoint exhibited significantly lower TIR and higher TAR across all trimesters, greater glycemic variability (CV) during the first (1T) and third trimesters (3T), and a higher glucose management indicator (GMI) in the third trimester. Logistic regression analysis showed that a TIR<!--> <!--><<!--> <!-->69.5% during the second trimester (2T) increased the risk of the composite endpoint by 10.56-fold (<em>P</em> <!-->=<!--> <!-->.015). Similarly, CV<!--> <!-->≥<!--> <!-->31.85% during the first trimester was associated with a 6.42-fold increased risk (<em>P</em> <!-->=<!--> <!-->.039). A model combining these 2 variables achieved a sensitivity of 94.3% and a specificity of 50%.</div></div><div><h3>Conclusions</h3><div>Glycemic control assessed through FGM metrics, particularly TIR during the second trimester and CV during the first trimester, is associated with adverse maternal–fetal outcomes in pregnant women with T1DM.</div></div>\",\"PeriodicalId\":48650,\"journal\":{\"name\":\"Endocrinologia Diabetes Y Nutricion\",\"volume\":\"73 7\",\"pages\":\"Article 501804\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2026-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Endocrinologia Diabetes Y Nutricion\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2530018026001198\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2026/9/15 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrinologia Diabetes Y Nutricion","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2530018026001198","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/9/15 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
Maternal and fetal outcomes associated with flash glucose monitoring metrics in women with type 1 diabetes: A cohort study
Objective
To evaluate the association between flash glucose monitoring (FGM) metrics and perinatal outcomes in pregnant women with type 1 diabetes (T1DM).
Research design and methods
This retrospective cohort study included pregnant women with T1DM who used FGM. The primary outcome was a composite endpoint including fetal or neonatal mortality, large-for-gestational-age (LGA) birth weight, neonatal intensive care unit (NICU) admission, or neonatal hypoglycemia. Glycated hemoglobin (HbA1c) levels were assessed together with time in range (TIR), time below range (TBR), and time above range (TAR) within pregnancy-specific glucose targets, as well as glucose variability.
Results
A total of 70 women were included, with a median age of 36 years (IQR, 31–38), body mass index (BMI) 27 ± 5 kg/m2, diabetes duration 20 ± 8 years, and pregestational HbA1c 7.3 ± 1.4%. Among them, 21.7% were smokers, 4.5% had hypertension, 10.1% had dyslipidemia, and 41.2% had diabetic retinopathy. Women who experienced the composite endpoint exhibited significantly lower TIR and higher TAR across all trimesters, greater glycemic variability (CV) during the first (1T) and third trimesters (3T), and a higher glucose management indicator (GMI) in the third trimester. Logistic regression analysis showed that a TIR < 69.5% during the second trimester (2T) increased the risk of the composite endpoint by 10.56-fold (P = .015). Similarly, CV ≥ 31.85% during the first trimester was associated with a 6.42-fold increased risk (P = .039). A model combining these 2 variables achieved a sensitivity of 94.3% and a specificity of 50%.
Conclusions
Glycemic control assessed through FGM metrics, particularly TIR during the second trimester and CV during the first trimester, is associated with adverse maternal–fetal outcomes in pregnant women with T1DM.
期刊介绍:
Endocrinología, Diabetes y Nutrición is the official journal of the Spanish Society of Endocrinology and Nutrition (Sociedad Española de Endocrinología y Nutrición, SEEN) and the Spanish Society of Diabetes (Sociedad Española de Diabetes, SED), and was founded in 1954.
The aim of the journal is to improve knowledge and be a useful tool in practice for clinical and laboratory specialists, trainee physicians, researchers, and nurses interested in endocrinology, diabetes, nutrition and related disciplines.
It is an international journal published in Spanish (print and online) and English (online), covering different fields of endocrinology and metabolism, including diabetes, obesity, and nutrition disorders, as well as the most relevant research produced mainly in Spanish language territories.
The quality of the contents is ensured by a prestigious national and international board, and by a selected panel of specialists involved in a rigorous peer review. The result is that only manuscripts containing high quality research and with utmost interest for clinicians and professionals related in the field are published.
The Journal publishes Original clinical and research articles, Reviews, Special articles, Clinical Guidelines, Position Statements from both societies and Letters to the editor.
Endocrinología, Diabetes y Nutrición can be found at Science Citation Index Expanded, Medline/PubMed and SCOPUS.